Study Answers Some Questions About Androgen Suppression Pre-Radiation, But Not All

    March 2015 in “ Oncology Times ”
    Robert H. Carlson
    TLDR Extending androgen suppression before radiotherapy offers no extra survival benefit for intermediate-risk prostate cancer.
    The RTOG 9910 trial, involving 1,489 men with intermediate-risk prostate cancer, found no additional benefit in extending androgen suppression from 8 to 28 weeks before radiotherapy, with similar 10-year survival outcomes. The study suggested that longer androgen suppression might not be necessary, although it used lower radiation doses than current standards. It did not determine if some men could avoid androgen suppression entirely, highlighting the need for further research, such as the RTOG 0815 trial, to assess the necessity and duration of androgen suppression. The document noted that radiation doses had increased since the trial, and previous studies showed survival benefits with shorter ADT durations, shifting the focus to whether ADT should be used at all due to its adverse effects.
    Discuss this study in the Community →

    Related Community Posts Join

    6 / 1000+ results

    Similar Research

    6 / 1000+ results
      Prostate Cancer Update: 2007

      research Prostate Cancer Update: 2007

      6 citations , May 2008 in “Current Opinion in Oncology”
      2007 research improved understanding of prostate cancer risk, diagnosis, and treatment, but also showed the need for personalized treatment and further study on certain therapies' risks.
      Prostate Cancer Update: 2007

      research Prostate Cancer Update: 2007

      August 2008 in “Current Opinion in Internal Medicine”
      In 2007, prostate cancer research improved understanding of risk, diagnosis, and treatment, but also showed heart risks with certain therapies and the need for personalized care.
      Table 2

      research Table 2

      December 2021
      Androgen suppression therapy (AST) doesn't significantly lower bladder cancer risk, but using finasteride, a type of AST, might decrease the risk. AST also lessens the chance of cancer coming back but doesn't really affect survival rates. More research is needed to understand AST's benefits for different bladder cancers.